We also show chemotherapy has a higher risk for myocardial infarction compared to PD-(L)1 monotherapy (OR = 0.44, 95% CI 0.34–0.58, q <  0.001), CTLA-4 monotherapy (OR = 0.56, 95% CI 0.36–0.85, q = 0.007), and combination immunotherapy (OR = 0.42, 95% CI 0.29–0.6, q <  0.001). Here, CTLA4 is linked to myocardial infarction.